Company news
Biorestorative Therapies, Inc. (NASDAQ:BRTX) news
Every Biorestorative Therapies, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
November 13, 2024
BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium
November 6, 2024
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
November 5, 2024
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
October 31, 2024
BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs
September 19, 2024
BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024
August 6, 2024
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
June 27, 2024
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
June 17, 2024
BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
May 24, 2024
BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market
May 15, 2024
BioRestorative Therapies Provides First Quarter 2024 Business Update
May 14, 2024
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity
May 8, 2024
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 30, 2024
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology
April 30, 2024
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
April 16, 2024
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
April 8, 2024
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
April 3, 2024
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
April 1, 2024
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
February 6, 2024
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
February 5, 2024
BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program
December 12, 2023
BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics
September 12, 2023
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
September 8, 2023
BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State
July 21, 2023
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering
July 11, 2023
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
July 7, 2023
BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes
June 27, 2023
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease
June 12, 2023
BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing
May 31, 2023
BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
May 15, 2023
BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial
May 8, 2023
BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100
April 24, 2023
BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100
March 13, 2023
BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
March 2, 2023
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
February 10, 2023
BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program
February 8, 2023
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
December 6, 2022
BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
December 5, 2022
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 30, 2022
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 22, 2022
BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 13, 2022
BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
April 29, 2022
BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
April 18, 2022
BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification
April 4, 2022
BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program
March 10, 2022
BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program
February 16, 2022
BioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway
February 7, 2022
BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio
February 2, 2022